New pill shows promise for aggressive brain cancer in early trial

NCT ID NCT05023551

Ongoing Disease control Sponsor: Sumitomo Pharma America, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 30, 2026 · Updated 3 times

Summary

This early-phase study tests an oral drug called DSP-0390 in 39 adults whose high-grade glioma (a fast-growing brain tumor) has come back after prior treatment. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants must be in fairly good health and have recovered from side effects of earlier therapies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DSP-0390 (an oral drug)
What this could lead to: If it works, this could point toward a new treatment option for people with recurrent high-grade glioma, a type of aggressive brain cancer.
What could go wrong: This is a very early, small study (39 people) focused on safety and dosing. It is not yet designed to prove the drug works, and many early-stage drugs fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA MULTIFORME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma glioma susceptibility 1 malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA MULTIFORME HIGH GRADE GLIOMA

Contacts and locations

Locations

Columbia University

New York, New York, 10032, United States
Dana Farber Cancer Institute

Boston, Massachusetts, 10032, United States
Hokkaido University Hospital

Sapporo, Hokkaido, 060-8648, Japan
Huntsman Cancer Institute, University of Utah

Salt Lake City, Utah, 84112, United States
John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States
Kyoto University Hospital

Kyoto, Sakyo-ku, 606-8507, Japan
National Cancer Center Hospital

Chuo Ku, Tokyo, 104-0045, Japan
University of California at San Francisco

San Francisco, California, 94143, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.